Bone metastasis microenvironment

The bone metastasis microenvironment refers to the specialized local tissue context in the bone that supports the seeding, survival, dormancy, and outgrowth of metastatic cancer cells, particularly those from breast, prostate, and lung cancers. Unlike single-molecule therapeutic targets, the microenvironment consists of a dynamic network of bone cells (osteoblasts, osteoclasts), stromal, immune, and endothelial cells, extracellular matrix proteins, and a range of signaling molecules and metabolites. Interactions among these elements regulate the "vicious cycle" of tumor growth and bone remodeling, which can result in either bone degradation (osteolytic metastasis) or abnormal bone formation (osteoblastic metastasis). Therapies aim to disrupt key molecular and cellular interactions within this environment, such as osteoclast activation (via RANKL), chemokine signaling (e.g., SDF-1/CXCR4), and hypoxia-related metabolic adaptation, to prevent or treat bone metastases. The microenvironment itself is not a molecule or druggable target in the strictest sense and, therefore, should not be catalogued as a conventional target (like a receptor or enzyme). It is best viewed as a therapeutic context or source of multiple potential targets rather than a single actionable molecular entity.

Other names

Bone metastatic nichebone tumor microenvironmentosseous microenvironmentskeletal metastatic microenvironment

Inhibiting bone resorption (osteoclast inhibition) Blocking ligand–receptor signaling in metastatic niche (e.g., CXCR4/SDF-1, RANK/RANKL, ET-1) Modulating microRNA activity to suppress osteoclastogenesis and metastasis (miR-34a) Interfering with growth factor signaling supportive of metastasis (e.g., IGF-1, SCUBE2, GDF15)